일성아이에스

003120KOSPI

48.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Ilshin IS is a pharmaceutical company specializing in penicillin antibiotics, collaborating with GSK, and producing key products like Augmentin, which generated 15,404 million won in sales. The company develops and sells medications across endocrine, digestive, and circulatory systems, achieving 64,292 million won in domestic sales during the 66th fiscal year.

Number of Employees

194people

Average Salary

51.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

128.24Industry Average 15.000.0Point

8.5x industry avg (risky)

PBR

0.75Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

0.30Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

0.31Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.2% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (32%)

Current 21,800Won52-week high 28,30052-week low 18,600

1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식소각결정2026-09-30
Neutral매매거래정지및정지해제(중요내용공시)2026-09-30